Clinical Trials Logo

Clinical Trial Details — Status: Enrolling by invitation

Administrative data

NCT number NCT03793231
Other study ID # 43127/MonH-2018-152967
Secondary ID 0120182015-54
Status Enrolling by invitation
Phase
First received
Last updated
Start date January 1, 2019
Est. completion date December 30, 2020

Study information

Verified date August 2020
Source Bayside Health
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This national Australian study will validate and implement an effective approach to real-time electronic surveillance of fungal infections in patients with blood cancers using technology based on artificial intelligence. It will establish metrics for antifungal stewardship allowing benchmarking of these programs; provide decision support for radiologist interpretation of chest imaging and improve reporting, audit and feedback practices in hospitals where these infections are managed.


Description:

Invasive fungal diseases (IFD) are rare infections that cause a life-threatening pneumonia in patients with weakened immune systems usually due to cancer chemotherapy and transplantation. Fungal spores are found in air, water and soil making exposure unavoidable in vulnerable patients. In developed countries, molds like Aspergillus are the most challenging type of IFD to diagnose and treat. These infections usually manifest as a culture-negative fungal pneumonia and account for approximately 300K of the 1.9M cases of IFD globally, but estimates are not accurate due to an absence of surveillance systems in hospitals where these infections are managed. Hospitals spend millions on antifungal drugs but are unaware of their patients affected, the effectiveness of their prevention efforts and hospital outbreaks may go unnoticed because surveillance, audit and feedback of fungal infections is not occurring. Optimising patient outcomes through timely diagnosis and appropriate prescribing of antifungal drugs is the goal of antifungal stewardship programs. Antifungal stewardship is of growing importance to hospitals world-wide because antifungal drugs are few in number, expensive to use and are associated with significant side-effects and drug interactions. Surveillance, audit and feedback are the cornerstones of antifungal stewardship programs that ensure patient care is meeting high standards. However, currently hospitals do not have the mechanisms to detect rare events like fungal infections because it usually presents as a pneumonia buried among hundreds of imaging scans. "fungalAiā„¢" (fungalAi.com) is a technology based on artificial intelligence (Ai) that uses existing data in hospitals to make real time surveillance of fungal infections possible and assist radiologist interpretation of diagnostic imaging. fungalAi does this through: 1. Natural language processing, a computational method of understanding human language. 2. Deep learning based image analysis of diagnostic imaging and 3. An expert system that integrates clinical data. What will be the impact? This project will provide hospitals with the mechanisms for performing real-time surveillance and audit of fungal infections in blood cancer patients through the innovative use of Ai. Strengthening antifungal stewardship through real-time surveillance of fungal diseases will improve patient care by revealing gaps in practice, new patient groups at risk for fungal infections and reduce inappropriate prescribing of antifungal medications through timely audit and feedback. The impact of this project will be: 1. Improved diagnosis and recognition of fungal infections. 2. Enhanced prevention. 3. More appropriate use of antifungal medications. FungalAi is a scalable technology that will be validated against active manual surveillance of fungal infections in a multi-centre Australian clinical trial. The inclusive approach of fungalAi means that it is of value to many vulnerable patients including neglected groups like children who are included in this project. FungalAi is tuned for detection of fungal pneumonia caused by molds because these infections are more diagnostically challenging than other types of fungal infections. As a result, fungalAi leverages chest computed tomography imaging because it is a critical diagnostic test that is widely available and performed more frequently than invasive tests like lung washings or biopsy. Hence fungalAi natural language processing may miss very rare manifestations like brain infections. Nevertheless, automating detection of fungal pneumonia and improving radiologist recognition of a rare disease using a self-improving system based on neural networks is an important step towards improving the supportive care of patients with cancer. Improving outcomes in cancer is not only about finding a cure. Reducing the impact of infectious threats like fungal diseases is just as important and this can now be achieved by integrating artificial intelligence into patient care.


Recruitment information / eligibility

Status Enrolling by invitation
Enrollment 1000
Est. completion date December 30, 2020
Est. primary completion date December 30, 2020
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group N/A and older
Eligibility Inclusion Criteria: - Adults and children - Under the haematology service at participating sites - Inpatient and ambulatory patients. Exclusion Criteria: No exclusion criteria

Study Design


Related Conditions & MeSH terms


Intervention

Combination Product:
fungalAi platform technology
Electronic surveillance and radiologic diagnosis of invasive fungal infections using fungalAi and associated methodologies.

Locations

Country Name City State
Australia Alfred Health Melbourne Victoria

Sponsors (8)

Lead Sponsor Collaborator
Bayside Health Eastern Health, Fremantle Hospital and Health Service, Monash Health, Monash University, SA Health, Singhealth Foundation, Western Sydney Local Health District

Country where clinical trial is conducted

Australia, 

Outcome

Type Measure Description Time frame Safety issue
Primary Accuracy of electronic surveillance using fungalAi natural language processing compared to active manual methods for detection of fungal pneumonia Sensitivity, specificity, ROC, Area under precision-recall curve of Ai assisted surveillance for fungal pneumonia using natural language processing of imaging reports compared to active manual surveillance 12 months
Secondary Accuracy of disease classification of deep learning based image analysis for fungal pneumonia at scan level. Sensitivity, specificity, ROC of deep learning based image analysis at scan level compared to active manual surveillance. 12 months
Secondary Accuracy of feature detection of fungal pneumonia using deep learning based image analysis of chest CT compared to radiologist expertise. Sensitivity, error rate (false positives, false negatives) at pixel level of deep learning based image analysis compared to radiologist labels. 12 months
Secondary Accuracy of disease classification of an expert system integrating microbiology and antifungal drug prescriptions with text and image analysis compared to active manual surveillance. Sensitivity, specificity, ROC, Area under precision-recall curve of Ai assisted surveillance compared to active manual surveillance that will only be performed at Alfred Health. 12 months
See also
  Status Clinical Trial Phase
Completed NCT01782131 - A Study of the Safety and Efficacy of Posaconazole Versus Voriconazole for the Treatment of Invasive Aspergillosis (MK-5592-069) Phase 3
Completed NCT02631954 - Phase I Clinical Trial for Comparison of Pharmacokinetic Characteristics of Vorico Injection 200mg(Voriconazole) and Vfend® IV 200mg for Single Dose Crossover Intravenous Infusion in Healthy Volunteers Phase 1
Completed NCT00177684 - Pharmacokinetic Profiles of Inhaled Lipid Complex Amphotericin B (Abelcet ®) Phase 3
Recruiting NCT01684189 - Registry of Febrile Neutropenia and Invasive Fungal Infections N/A
Completed NCT00794703 - A Study to Compare Efficacy and Safety of Mycamine® and Itraconazole for Preventing Fungal Infections Phase 3
Completed NCT00606268 - A Study of Safety and Pharmacokinetics of Repeated Dose of Micafungin as Antifungal Prophylaxis in Children and Adolescents Who Undergo Hematopoietic Stem Cell Transplant Phase 1
Completed NCT00353158 - A Pilot of Pediatric/Adult Study of Gene Expression Profiling and Clinical Characterization of Phototoxicity Phase 1
Completed NCT01777763 - Pharmacokinetics and Safety of Posaconazole Tablet in Participants at High Risk for Invasive Fungal Infections (MK-5592-065/P05615) Phase 1
Recruiting NCT01222741 - Studies of Disorders With Increased Susceptibility to Fungal Infections
Completed NCT02358499 - Genetic Variation and Variability in Posaconazole Pharmacokinetics in Children Phase 1
Completed NCT00177710 - Pharmacokinetic Profile of Inhaled Liposomal Amphotericin B in Lung Transplant Recipients - Ambisome Study Phase 3
Completed NCT02025699 - Prospective Study to Characterize Host-pathogen Related Factors in Hospitalized and ED Patients With LRTI and/or Sepsis N/A
Completed NCT01436578 - Safety and Efficacy of Posaconazole Oral Suspension in Usual Practice in Korea (P08547) N/A
Completed NCT00876096 - Interest of Real-time Polymerase Chain Reaction (PCR) in the Diagnosis of Fungal Infections N/A
Completed NCT02306330 - MALDITOF Versus Routine Clinical Microbiology for Identifying Pathogens; a Randomized Diagnostic Trial N/A
Not yet recruiting NCT01105013 - Evaluate the Efficacy and Safety of Tolnaftate Cream in the Treatment of Patients With Fungal Infections Phase 3
Terminated NCT01716234 - A Study of the Safety, Tolerance, and Pharmacokinetics of Oral Posaconazole in Immunocompromised Children (P03579) Phase 1
Recruiting NCT05336851 - Emergency PWAS in Respiratory Infectious Disease

External Links